- IXICO, the brain health company, has signed a new contract worth US$1.5m for its imaging clinical trial technologies and services with an existing customer which is a top 10 pharmaceutical company.

The contract is for the supply of services to a phase IIb clinical trial of patients in the early stages of Progressive Supranuclear Palsy, a Parkinson's-like neurodegenerative condition caused by the premature loss of nerve cells in certain parts of the brain.

IXICO will collect, manage and analyse MRI scans acquired at over 90 international specialist imaging centres utilising its proprietary TrialTracker platform.

This data analytics technology has been specifically modified for quantifying drug effects in PSP patients.

This current study is expected to complete in 2020 and there is potential for the scope to be extended further.

At 9:43am: [LON:IXI] IXICO plc share price was +1p at 30.25p

Story provided by